Clinical Trial

A PhaseⅠ Study of HW252001 in Healthy Subjects

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, randomized, double-blind, placebo-controlled, Single/multiple ascending doses (SAD/MAD) study of HW252001 in healthy subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and Pharmacodynamics of HW252001.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-20.
Trial Details
NCT Number NCT07493031
Lead Sponsor Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Conditions IPF
Enrollment 98 participants
Start Date 2026-03-31
Primary Completion 2026-12-11 (estimated)
Study Completion 2026-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-27